Can Fite Biopharma

CANF · TEL

$1.78−$0.05 (−2.73%)TodayMarket closed · Oct 23, 8:00 PM ET

Prev close $1.83

About CANF

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 5 full-time employees. The company went IPO on 2005-09-22. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Employees: 5
Headquarters: Petah Tikva, Central(HaMerkaz)
Listed: Sep 22, 2005
Sector: Health Care
Industry: Biotechnology
Website: canfite.com

Leadership

Can Fite Biopharma executives
Name	Title	Since	Age
Ilan Cohen	—	1994	—
Pnina Fishman	—	1994	73
Motti Farbstein	—	—	59
Sari Fishman	—	—	50
Yoseph Borenstein	—	—	—
Yaacov Goldman	—	—	67
Guy Regev	—	—	50
Abraham Sartani	—	—	75

Similar companies

Companies in the same industry as Can Fite Biopharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.